Inventor · disambiguated record
Glenn Pierce
Also filed as: PIERCE GLENN · PIERCE GLENN F · PIERCE GLENN FRANCIS
32 granted patents·14 pending applications·607 citations·filing 1994–2024
98Inventor score
Files withBIOVERATIV THERAPEUTICS INC21AMGEN INC6BAYER HEALTHCARE LLC3BIOGEN HEMOPHILIA INC3DUMONT JENNIFER A2
Top patents by PatentIndex Score
46 records- 0198US9867873B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2015·Granted Jan 16, 2018·17 cites·25 claims
- 0298US9675676B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Jun 13, 2017·19 cites·30 claims
- 0398US9629903B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 25, 2017·17 cites·29 claims
- 0498US9623091B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2016·Granted Apr 18, 2017·16 cites·28 claims
- 0597US10898554B1Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 26, 2021·6 cites·22 claims
- 0696US10568943B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Feb 25, 2020·6 cites·18 claims
- 0796US9233145B2Factor IX polypeptides and methods of use thereofBIOGEN HEMOPHILIA INC·Filed 2013·Granted Jan 12, 2016·27 cites·22 claims
- 0895US10548954B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2020·5 cites·16 claims
- 0994US11266720B2Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 8, 2022·6 cites·64 claims
- 1094US9670475B2Factor IX polypeptides and methods of use thereofPIERCE GLENN·Filed 2011·Granted Jun 6, 2017·18 cites·34 claims
- 1193US10881742B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Jan 5, 2021·5 cites·26 claims
- 1293US10561714B2Factor IX polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2018·Granted Feb 18, 2020·3 cites·20 claims
- 1393US9050318B2Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereofDUMONT JENNIFER A·Filed 2010·Granted Jun 9, 2015·28 cites·31 claims
- 1491US5418222AMulti-layered collagen film compositions for delivery of proteins and methods of using sameAMGEN INC·Filed 1994·Granted May 23, 1995·130 cites·45 claims
- 1590US11286528B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2019·Granted Mar 29, 2022·4 cites·14 claims
- 1690US9241978B2Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereofBIOGEN HEMOPHILIA INC·Filed 2013·Granted Jan 26, 2016·15 cites·21 claims
- 1788US12186375B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Jan 7, 2025·1 cites·19 claims
- 1888US11225650B2Methods of using FIX polypeptidesBIOVERATIV THERAPEUTICS INC·Filed 2017·Granted Jan 18, 2022·5 cites·20 claims
- 1986US2025195620A1Factor viii chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2084US10010622B2Factor VIII chimeric and hybrid polypeptides, and methods of use thereofDUMONT JENNIFER A·Filed 2012·Granted Jul 3, 2018·7 cites·22 claims
- 2184US5824643ATherapeutic uses of keratinocyte growth factorAMGEN INC·Filed 1995·Granted Oct 20, 1998·53 cites·24 claims
- 2283US7534774B2Traversal of nucleic acid molecules through a fluid space and expression in repair cellsTISSUE REPAIR COMPANY·Filed 2002·Granted May 19, 2009·15 cites·3 claims
- 2382US10221455B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2013·Granted Mar 5, 2019·5 cites·25 claims
- 2479US6613563B1Viral vectors with modified tropismSELECTIVE GENTICS INC·Filed 1998·Granted Sep 2, 2003·55 cites·7 claims
- 2579US5858977AMethod of treating diabetes mellitus using KGFAMGEN INC·Filed 1995·Granted Jan 12, 1999·50 cites·11 claims
- 2678US5814605ATherapeutic uses of keratinocyte growth factorAMGEN INC·Filed 1995·Granted Sep 29, 1998·36 cites·5 claims
- 2777US2022265780A1Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2875US12371747B2Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapyBIOVERATIV THERAPEUTICS INC·Filed 2022·Granted Jul 29, 2025·0 cites·17 claims
- 2975US6689351B1Use of GM-CSF to promote accelerated wound healingAMGEN INC·Filed 1994·Granted Feb 10, 2004·34 cites·12 claims
- 3074US2021008178A1Factor ix polypeptides and methods of use thereofBIOVERATIV THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3173US2018207244A1Factor IX Polypeptides and Methods of Use ThereofBIOVERATIV THERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 3271US2010086598A1Traversal of nucleic acid molecules through a fluid space and expression in repair cellsTISSUE REPAIR COMPANY·Filed 2009·Application pending·0 cites
- 3370US9422362B2Targeted coagulation factors and method of using the sameBAYER HEALTHCARE LLC·Filed 2014·Granted Aug 23, 2016·0 cites·15 claims
- 3470US2022064622A1Methods of using fix polypeptidesBIOVERATIV THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3568US10656167B2Assays to monitor bleeding disordersSOMMER JURG·Filed 2012·Granted May 19, 2020·2 cites·13 claims
- 3667US11747351B2Assays to monitor bleeding disordersBIOVERATIV THERAPEUTICS INC·Filed 2020·Granted Sep 5, 2023·0 cites·15 claims
- 3765US5965530ATherapeutic uses of keratinocyte growth factorAMGEN INC·Filed 1995·Granted Oct 12, 1999·22 cites·23 claims
- 3864US2011077202A1Targeted Coagulation Factors and Method of Using the SameBAYER HEALTHCARE LLC·Filed 2009·Application pending·0 cites
- 3963US10035840B2Targeted coagulation factors and method of using the sameBAYER HEALTHCARE LLC·Filed 2016·Granted Jul 31, 2018·0 cites·15 claims
- 4056US2015252345A1Methods of Using FIX PolypeptidesBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 4155US2013190391A1Traversal of nucleic acid molecules through a fluid space and expression in repair cellsSOSNOWSKI BARBARA A·Filed 2012·Application pending·0 cites
- 4254US2016199455A1Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use ThereofBIOGEN HEMOPHILIA INC·Filed 2015·Application pending·0 cites
- 4351US2011286988A1FVIII Muteins for Treatment of Von Willebrand DiseaseJIANG HAIYAN·Filed 2009·Application pending·0 cites
- 4447US2004029280A1Viral vectors with modified tropismSELECTIVE GENETICS INC·Filed 2003·Application pending·0 cites
- 4545US2003040496A1Methods for halting unwanted cell growth, such as using ligand-directed nucleic acid delivery vehiclesFiled 2001·Application pending·0 cites
- 4641US2001044413A1In situ bioreactors and methods of use thereofFiled 2000·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn Pierce files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →